Fracture risk evaluation, clinical algorithm and osteoporosis drug effects in diabetes

Diabetes Mellitus (DM) is one of the significant chronic metabolic diseases requiring continuous medical attention including multifactorial risk-reduction strategies beyond glycaemic control. It is a risk factor for osteoporosis, leading to increased risk of fracture, and ultimately reduced quality of life, and considerable morbidity and mortality.

In this course, Professor Serge Ferrari will review the pathophysiology of bone fragility in diabetes. He will summarise the current understanding of the association between bone turnover markers and low bone mineral density/ bone fragility in diabetes. He will also summarise the evaluation of other biochemical markers and hormones in this context and discuss their clinical implications.

Key Learning Objectives of this course include:

• To review the pathophysiology of bone fragility in diabetes
• To learn how to evaluate fracture risk in these patients
• To gain knowledge of the pharmacological management of bone fragility in diabetic patients